2035世界杯官方入口
We strategically prioritise sourcing innovation externally, recognising that some of the most transformative science emerges from biotech and academic institutions. At the same time, we leverage our internal scientific engine to accelerate and amplify these breakthroughs.
We focus with intent on select indications and therapeutic areas where our passion for innovation, commitment to meaningful clinical impact, and drive to set new standards can deliver tangible benefits for patients. This distinctive approach has earned the trust of leading talents from pharma, biotech, and academia, who join us to shape the future through bold, collaborative science.
2035世界杯官方入口
We leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease, and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation and bring new medicines to patients.
2035世界杯官方入口
2035世界杯官方入口
Since 2020, Ipsen has brought in more than 30 best- or first-in-class programs across our pipeline at every stage of development and our approach is to continue this momentum.
We now have 7 assets projected to deliver >€500m sales by 2026; this was achieved together with our partners through accelerating, de-risking & maximising the scope of these programs.
We intend to continue building this strong future for Ipsen through further collaborations and acquisitions to bring transformative medicines to patients.
2035世界杯官方入口
Explore our key milestones and partnering successes. ?
Impact across the globe
Represented in 88 countries, our commercial sales have strong coverage across Europe (39%), North America (34%), ?the rest of the world (26%) with our medicines showing strong commercial performance.
Connecting patients to our therapies
5,000 colleagues in more than 40 countries, and our partnerships around the world, enable us to bring medicine to patients in >100 countries.
Solidifying oncology partnerships ?
Ipsen has finalized several licensing agreements, adding innovative modalities – such as antibody-drug conjugates and T cell engagers – to our early development pipeline. We also secured a licensing agreement with Day One Pharmaceuticals for a first-in-class treatment for pediatric low-grade glioma, expanding new possibilities for this patient group.
New modalities in neuroscience
In 2024, we entered an exclusive global collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
Marengo Case Study
Find out more about how we approach partnerships at Ipsen, where every program is a priority within our pipeline. We sat down with Zhen Su, CEO Marengo, to discuss our partnership and how we undertake a one team approach to accelerate innovation for the patients who are waiting
Learn more2035世界杯官方入口
At Ipsen, partnering is personal and purpose-led. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
Investors
At Ipsen, we see investors as vital partners in advancing our mission. Ipsen provides comprehensive investor information, including our financial updates, reports and events calendar, plus shareholder news and regulated information in our dedicated investor pages.
Learn more
